Literature DB >> 10463394

Doxorubicin induces male germ cell apoptosis in rats.

K Shinoda1, K Mitsumori, K Yasuhara, C Uneyama, H Onodera, M Hirose, M Uehara.   

Abstract

To clarify whether apoptosis is involved in doxorubicin (DXR)-induced testicular toxicity and to identify the target germ cell type, adult Sprague-Dawley rats were treated with a single intravenous dose of DXR (8 or 12 mg/kg) and euthanized at 3, 6, 12, 24, and 48 h subsequently. Histologically, germ cell degeneration was first found 6 h after dosing in meiotically dividing spermatocytes and early round spermatids of seminiferous tubules at stage 1, and subsequently observed in spermatogonia at stages I-VI showing ultrastructural characteristics of apoptosis. Coincident with the appearance of morphological changes, degenerating germ cells were shown to be undergoing apoptosis as revealed by in situ terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). The frequency of TUNEL-labeled germ cells increased in a stage- and cell type-specific manner, the peak of frequency gradually progressing from stage I of seminiferous tubules to later stages with time after dosing, suggesting that the damaged germ cells, especially spermatogonia, gradually underwent the processes leading to apoptosis. DNA laddering on gel electrophoresis was apparent 24 and 48 h after dosing. The results demonstrate that apoptosis plays an important role in the induction of testicular toxicity caused by DXR with meiotically dividing spermatocytes and type A and intermediate spermatogonia as highly vulnerable target cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10463394     DOI: 10.1007/s002040050617

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  9 in total

Review 1.  Morphologic manifestations of testicular and epididymal toxicity.

Authors:  Justin D Vidal; Katharine M Whitney
Journal:  Spermatogenesis       Date:  2014-12-31

2.  Perturbation of epigenetic processes by doxorubicin in the mouse testis.

Authors:  Oluwajoba O Akinjo; Timothy W Gant; Emma L Marczylo
Journal:  Toxicol Res (Camb)       Date:  2016-06-01       Impact factor: 3.524

3.  A standardized extract of Ginkgo biloba suppresses doxorubicin-induced oxidative stress and p53-mediated mitochondrial apoptosis in rat testes.

Authors:  Y-C Yeh; T-J Liu; L-C Wang; H-W Lee; C-T Ting; W-L Lee; C-J Hung; K-Y Wang; H-C Lai; H-C Lai
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

4.  Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent.

Authors:  Elon C Roti Roti; Scott K Leisman; David H Abbott; Sana M Salih
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

5.  Sertoli cell function in albino rats treated with etoposide during prepubertal phase.

Authors:  Taiza Stumpp; Edna Freymüller; Sandra Maria Miraglia
Journal:  Histochem Cell Biol       Date:  2006-03-21       Impact factor: 2.531

6.  Perturbation of microRNA signalling by doxorubicin in spermatogonial, Leydig and Sertoli cell lines in vitro.

Authors:  Oluwajoba O Akinjo; Timothy W Gant; Emma L Marczylo
Journal:  Toxicol Res (Camb)       Date:  2018-05-16       Impact factor: 3.524

7.  Amifostine reduces the seminiferous epithelium damage in doxorubicin-treated prepubertal rats without improving the fertility status.

Authors:  Vanessa Vendramini; Estela Sasso-Cerri; Sandra M Miraglia
Journal:  Reprod Biol Endocrinol       Date:  2010-01-10       Impact factor: 5.211

8.  Crataegus monogyna fruit aqueous extract as a protective agent against doxorubicin-induced reproductive toxicity in male rats.

Authors:  Ali Shalizar Jalali; Shapour Hasanzadeh
Journal:  Avicenna J Phytomed       Date:  2013

9.  Adverse Effects of Vincristine Chemotherapy on Cell Changes in Seminiferous Tubules and Cetrorelix GnRH Antagonistzzm321990Inhibitory Effects in Mice

Authors:  Fatemeh Nikpour; Hamid Tayefi; Daryosh Mohammadnejad; Abolfazl Akbarzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.